A lecturer and his research team from Faculty of Veterinary Science, Chulalongkorn University, have developed “FLAVO INNOVAC” nanovaccine for the prevention of bacterial gills diseases in freshwater fish species such as Tilapia and freshwater Asian sea bass. This nanovaccine is an effective solution that reduces the risk of death from diseases and the limitations of vaccine injections. university in thailand
Tilapia and Asian sea bass are the economically important fish species in the market but raising them to be healthy is a painstaking task, especially when faced with the possibility of disease outbreaks such as infections from Flavobacterium commonly found in raising water environments. The problem worsens with the over-crowding of fish in ponds and other risk factors that promotes the spread of bacteria resulting in gills disease. The disease can cause massive mortality of fish.
For this reason, Associate Professor Dr. Channarong Rodkhum has formed a collaborative effort with a research team from the Center of Excellence in Fish Infectious Diseases (CE FID) and Aqua Innovac Co. Ltd. to develop “FLAVO INNOVAC” the world’s first inactivated Flavobacterium nanovaccine.
“Normally fish farming or aquatic industries do experience diseases and infections. Overcrowding, bad environments and water quality, increase of organic substances, or changes in water temperatures can weaken the fish making them susceptible to diseases. Flavobacterium spp. is the causative agent that attacks fish and causes gills and skin infections leading to as high as up to 100 % mortality rates, especially among the juvenile stage of fish that are still weak and cannot specifically protect themselves from Flavobacterium spp. infections. This can be prevented by administering a vaccine for these fish.” Associate Professor Dr. Channarong Rodkhum explained.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น